Vaxart, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Vaxart, Inc. (VXRT) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its S-1 filed 2026-05-08.
Financial Statements › Expense Statement
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-05-08
- Vaxart, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- Vaxart, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
- Vaxart, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $0.00.
- Vaxart, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 S-1 · filed 2026-05-08 |
| 2024-12-31 | $0.00 S-1 · filed 2026-05-08 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |